NCT03878433View on ClinicalTrials.gov

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

January 1, 2020

Study Completion Date

July 1, 2020

Conditions
Melasma
Interventions
DRUG

Glisodin

500 mg/day between 12 weeks

OTHER

placebo

Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months

Trial Locations (1)

06001

CHU de Nice - Dermatology, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT03878433 - Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. | Biotech Hunter | Biotech Hunter